Lumito Arrow right Arrow right

Lumito signs cooperation agreement with Optronic for 0-series production of the company's scanner



Lumito AB and Optronic Partner pr AB have signed a cooperation agreement for the final design, industrialization and 0-series production of Lumito's first Whole Slide Imaging (WSI) scanners. The scope of the agreement is based on the delivery of 0-series production prior to Lumito's planned launch for research laboratories at the end of 2022. The collaboration is based on well-defined delivery points before the end of the year, such as the design phase, product verification phase and the 0-series production phase.

 

Optronic is a service provider that is industry-leading in the Nordic region in the development and manufacture of optical sensors for the industry. The combination of specialist competence in optronics and a cost-effective production with high quality, is one of the company's main success factors. The company has 60 employees and is owned by Dacke Industri, which in turn is owned by Nordstjernan.

 

- Optronic is a strategically valuable partner and I look forward to our joint work on completing the final design of Lumito's scanner and production planning. Through the agreement with Optronic, we have taken another step, as foreseen, towards the planned commercialization at the end of the year, says Lumito's CEO Mattias Lundin.

 

Lumito's WSI scanner is an optical analysis instrument that, together with the company's UCNP-based staining liquids, enables researchers and pathologists to take high-contrast digital images of tissues. The scanner can also take pictures of traditionally stained tissue samples (hematoxylin staining and immunohistochemistry).

 

- We are honored that Lumito chooses us as a partner. Optical technology will play a significant role in realizing future healthcare solutions and we have over time developed our offering to meet the industry's high demands. We look forward to an exciting, long-term and strategic collaboration, says Ulrik Stenbacka, CEO of Optronic.

 

This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out in this press release, at 10:00 am on 13 April 2022.

 

For further information, please contact:
 

Lumito’s CEO, Mattias Lundin

E-mail: ml@lumito.se

phone: +46 76-868 45 09

 

 

 

 

 

Optronic is a Nordic leader in optical measurement technology. The company specializes in the development and manufacturing of products and modules containing optics, photonics and advanced electronics. The offer covers the entire product life-cycle and focuses on helping industrial companies to realize development opportunities, and to manufacture cost effectively with guaranteed high quality. Since the company was founded in 1987, Optronic has helped more than 500 customers with over 1,000 different challenging projects. The production facility covers approximately 3,000 square meters, with manufacturing equipment optimized to meet the requirements of the most demanding industrial segments, including automation, logistics, medical technology, security, transport and agriculture. Optronic has 60 employees and is located in Skellefteå and Stockholm, and in Lahti, Finland. www.optronic.se

 

 

Lumito specializes in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalized healthcare. The technology enables higher contrast images where unimportant background information is sorted out, making it easier for pathologists to find cancer indications. The technology, based on Up Converting Nano Particles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shorter analysis times. The method has several potential applications, but Lumito has chosen to focus primarily on digital pathology. The company is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Centre. www.lumito.se.

 

The share is traded on NGM Nordic SME, under the name LUMITO and Mentor is Mangold Fondkommission, phone: +46 (8) 5030 1550 and email, ca@mangold.se.

 

 

 



PDF:
Taggar:

Subscribe

Content

When submitting a subscription to press releases, quarterly reports and annual reports, your email address will be forwarded to Cision, which handles the mailing service. For more information, see Lumito's Privacy Policy.